Cardio Diagnostics Holdings, Inc.

Listed Company

CDIOCIK 0001870144NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthIn Vitro & In Vivo Diagnostic SubstancesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$14.8K

Net Income

$-6.50M

Total Assets

$7.77M

Equity

$6.97M

Shares Out

2.96M

Op. Cash Flow

$-5.73M

Business

Cardio Diagnostics Holdings, Inc. develops and commercializes diagnostic solutions that assess and detect cardiovascular disease using a proprietary AI-driven Integrated Genetic-Epigenetic Engine™. Its main products and services include clinical blood tests Epi+Gen CHD™ and PrecisionCHD™, a provider-facing Actionable Clinical Intelligence™ platform, the HeartRisk™ SaaS risk intelligence product, and the CardioInnovate360™ research-use-only solution. Key business areas comprise laboratory-developed testing and associated laboratory services, software/SaaS analytics, and RUO research solutions with strategic partnerships. The company distributes products primarily in the United States through providers, health systems, telemedicine, concierge practices, employers, payors and marketplaces.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	14,825	34,890	17,065	950	901
Sales and marketing	766,888	1	158,514	92,700	103,318
Research and development	641,212	227,966	145,182	40,448	31,468
General and administrative	5	7	7	4	470,563
Amortization	65,233	19,738	19,182	16,000	16,000
Total operating expenses	6	8	7	5	621,349
Loss from operations	−6	−8	−7	−5	−620,448
Interest income	712	1,064	1,068	—	—
Interest expense	−14,801	−18,640	−7	—	—
Total other income (expenses)	−14,089	−17,576	−1	−112,534	—
Loss before provision for income taxes	−6	−8	−8	−5	−620,448
Provision for income taxes	—	—	—	—	0
Net loss	−6	−8	−8	−5	−620,448
Net loss per common share, basic	−3.71	−9.35	−0.66	−1.51	−0.53
Net loss per common share, diluted	−3.71	−9.35	−0.66	−1.51	−0.53
Weighted average common shares outstanding, basic	2	896,424	13	3	1
Weighted average common shares outstanding, fully diluted	2	896,424	13	3	1

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-07-31	FY 2022 2022-12-31
Cash	5	8	1	—	4
Accounts receivable	8,126	18,612	4,960	—	—
Prepaid expenses and other current assets	801,947	944,683	1	—	2
Total current assets	6	9	3	—	6
Property and equipment, net	700,115	672,861	571,873	—	—
Right of use assets, net	259,565	432,397	575,227	663,875	—
Intangible assets, net	—	5,333	21,333	—	37,333
Deposits	12,850	12,850	12,850	—	4,950
Patent costs, net	873,182	701,089	515,402	—	321,308
Total assets	8	11	4	—	6
Accounts payable and accrued expenses	97,442	87,661	243,213	—	1
Lease liability - current	237,607	237,270	223,929	—	—
Finance agreement payable	269,790	306,764	374,000	—	849,032
Total current liabilities	604,839	631,695	841,142	—	2
Lease liability - long term	188,222	425,829	663,099	—	—
Total liabilities	793,061	1	2	—	2
Preferred stock, $.00001 par value; authorized - 100,000,000 shares; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively	—	—	—	—	—
Common stock, $.00001 par value; authorized - 300,000,000 shares; 1,826,051 and 1,531,468 shares issued and outstanding as of December 31, 2025 and 2024, respectively	18	15	205	—	95
Additional paid-in capital	36	32	17	—	10
Accumulated deficit	−29	−23	−14	—	−6
Total stockholders' equity	7	10	3	—	4
Total liabilities and stockholders' equity	8	11	4	—	6

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	160,063	113,777	3,790	0	—
Amortization	238,065	162,568	107,830	16,000	16,000
Stock-based compensation expense	110,235	3	1	—	60,000
Accounts receivable	10,486	−13,652	−4,960	901	−901
Prepaid expenses and other current assets	479,974	915,969	758,669	−690,821	—
Accounts payable and accrued expenses	9,781	−155,552	−781,500	136,353	−5,654
Lease liability	−237,270	−223,929	244,505	—	—
NET CASH USED IN OPERATING ACTIVITIES	−6	−5	−6	−5	−585,291
Purchases of property and equipment	−187,317	−214,765	−575,663	—	—
Patent costs incurred	−231,993	−189,425	−197,276	−76,154	−114,029
NET CASH USED IN INVESTING ACTIVITIES	−419,310	−404,190	−794,291	−368,001	−364,029
Proceeds from sale of common stock and warrants, net of issuance costs	4	12	—	12	105,000
Payments of finance agreement	−374,212	−450,691	−942,532	−188,674	—
NET CASH PROVIDED BY FINANCING ACTIVITIES	3	12	4	9	1
NET (DECREASE) INCREASE IN CASH	−3	7	−3	4	275,680
Interest	14,801	18,640	30,491	5,829	0
Income taxes	—	—	—	—	—
Financing agreement entered into for prepaid insurance	337,238	383,455	467,500	1	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro